Therefore, therapeutic overexpression or CNS administration of these ADNP- or VGF-derived peptides have the potential to prevent the progression of comorbid neuropsychiatric and neurodegenerative diseases. The gene discussed is ADNP; the disease is neurodegenerative disease.